Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea
{"title":"透析器东丽 NV-U® Hydrolink™ 对介质分子的去污能力:用于进行在线血液渗滤的新型亲水膜。","authors":"Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea","doi":"10.1177/03913988241274735","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U<sup>®</sup> has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.</p><p><strong>Methods: </strong>This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000<sup>®</sup> (FMC). Subsequently, the dialyzer was changed to TORAY NV-U<sup>®</sup> (Hydrolink<sup>®</sup>) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.</p><p><strong>Results: </strong>We did not find differences in medium size removal molecules and convective volume: FX1000<sup>®</sup>: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; <i>p</i> = 0.7); β2microglobulin reduction ratio (RR) FX1000<sup>®</sup> FMC 83 ± 3%; Hydrolink™ 79 ± 4; <i>p</i> = 0.14; Myoglobin RR FX1000<sup>®</sup> FMC 72 ± 7%; Hydrolink™ 76 ± 4; <i>p</i> = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000<sup>®</sup> 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; <i>p</i> = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had \"good\" dialyzer status in all dialysis sessions with TORAY NV-U<sup>®</sup>, while the dialyzer status with FX1000<sup>®</sup> was \"good\" in 20% of the sessions, \"medium\" in 30%, and \"dirty\" in the remaining 50% dialysis sessions.</p><p><strong>Conclusions: </strong>The new dialyzer Hydrolink™, TORAY NV-U<sup>®</sup> is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Depurative capacity toward medium molecules of the dialyzer Toray NV-U<sup>®</sup> Hydrolink™: A new hydrophilic membrane to perform online hemodiafiltration.\",\"authors\":\"Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea\",\"doi\":\"10.1177/03913988241274735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U<sup>®</sup> has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.</p><p><strong>Methods: </strong>This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000<sup>®</sup> (FMC). Subsequently, the dialyzer was changed to TORAY NV-U<sup>®</sup> (Hydrolink<sup>®</sup>) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.</p><p><strong>Results: </strong>We did not find differences in medium size removal molecules and convective volume: FX1000<sup>®</sup>: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; <i>p</i> = 0.7); β2microglobulin reduction ratio (RR) FX1000<sup>®</sup> FMC 83 ± 3%; Hydrolink™ 79 ± 4; <i>p</i> = 0.14; Myoglobin RR FX1000<sup>®</sup> FMC 72 ± 7%; Hydrolink™ 76 ± 4; <i>p</i> = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000<sup>®</sup> 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; <i>p</i> = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had \\\"good\\\" dialyzer status in all dialysis sessions with TORAY NV-U<sup>®</sup>, while the dialyzer status with FX1000<sup>®</sup> was \\\"good\\\" in 20% of the sessions, \\\"medium\\\" in 30%, and \\\"dirty\\\" in the remaining 50% dialysis sessions.</p><p><strong>Conclusions: </strong>The new dialyzer Hydrolink™, TORAY NV-U<sup>®</sup> is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.</p>\",\"PeriodicalId\":13932,\"journal\":{\"name\":\"International Journal of Artificial Organs\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Artificial Organs\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1177/03913988241274735\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/03913988241274735","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Depurative capacity toward medium molecules of the dialyzer Toray NV-U® Hydrolink™: A new hydrophilic membrane to perform online hemodiafiltration.
Introduction: New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U® has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.
Methods: This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000® (FMC). Subsequently, the dialyzer was changed to TORAY NV-U® (Hydrolink®) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.
Results: We did not find differences in medium size removal molecules and convective volume: FX1000®: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; p = 0.7); β2microglobulin reduction ratio (RR) FX1000® FMC 83 ± 3%; Hydrolink™ 79 ± 4; p = 0.14; Myoglobin RR FX1000® FMC 72 ± 7%; Hydrolink™ 76 ± 4; p = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000® 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; p = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had "good" dialyzer status in all dialysis sessions with TORAY NV-U®, while the dialyzer status with FX1000® was "good" in 20% of the sessions, "medium" in 30%, and "dirty" in the remaining 50% dialysis sessions.
Conclusions: The new dialyzer Hydrolink™, TORAY NV-U® is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.
期刊介绍:
The International Journal of Artificial Organs (IJAO) publishes peer-reviewed research and clinical, experimental and theoretical, contributions to the field of artificial, bioartificial and tissue-engineered organs. The mission of the IJAO is to foster the development and optimization of artificial, bioartificial and tissue-engineered organs, for implantation or use in procedures, to treat functional deficits of all human tissues and organs.